ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY
    3.
    发明申请
    ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY 有权
    具有增强补充活性的抗体变体

    公开(公告)号:US20130122001A1

    公开(公告)日:2013-05-16

    申请号:US13747317

    申请日:2013-01-22

    IPC分类号: C07K16/28

    摘要: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.

    摘要翻译: 本发明涉及包含至少一个可提供增强的效应子功能的新的氨基酸残基的新型Fc变体。 更具体地,本发明提供了对一种或多种Fc受体或配体(例如FcγR,C1q)具有修饰的结合亲和力的Fc变体。 另外,Fc变体具有改变的补体依赖性细胞毒性(CDC)活性和/或抗体依赖性细胞介导的细胞毒性(ADCC)。 本发明还提供了用于应用所述Fc变体的方法和方案,特别是用于治疗目的。